Clear Webinar Cannabis and Celebrations!

May 16, 2019





Please note:


This webinar is being recorded

Personal information in this initiative is collected under s.26(c) and 26(d)(ii) of the Freedom of Information and Protection of Privacy Act. The information is being collected in order to facilitate training and education as part of Clear. This webinar is being recorded and will be shared with program participants. We ask that you refrain from identifying patients, specific team members or offering any other personal information. If you have further questions, please contact the BCPSQC at 604 668 8210 or clear@bcpsqc.ca.





Interacting in WebEx









Aberdeen Hospital		Qualicum Manor
Augustine House/Haven House		Renfrew Care Centre
Beacon Hill Villa		Richmond Lions Manor Bridgeport
Bevan Lodge Residential		Rosemary Heights Seniors Village
Comox Valley Seniors Village		Rotary Manor
Cumberland Lodge		Royal City Manor
Dufferin Care Centre		Selkirk Place (Selkirk Seniors Village)
Elim Village, The Harrison/Harrison West		Shorncliffe
Glacier View Lodge		Simon Fraser Lodge
Good Samaritan Wexford Creek		Stanford Place
Gorge Road Hospital		The Pines
Guildford Seniors		The Residence at Morgan Heights
Heritage Square		The Residence in Mission
Jackman Manor		Valhaven Rest Home
Kamloops Seniors Village		Valleyhaven
Kiwanis Village Lodge		Waverly-Grosvenor House Ventures
Louis Brier Home and Hospital		Willingdon Creek Village
Maple Ridge Seniors Village		Woodgrove Manor
Nanaimo Seniors Village		Yucalta Lodge
Nanaimo Traveller's Lodge (Eden Gardens)		
Peace Villa		
Powell River General Hospital	D	on't see your name? Use the text

tool to tell us in the Chatbox!







CLEAR TEAM CELEBRATION VIDEOS





Yucalta Lodge

Clear Committee members, past and present:

- Danielle Girard
- Deena Johnson
- Chris MacDonald
- Helen Wackerman
- Lisa Sparling-White
- Emily Smith
- Marcy Lysy
- Cindy Fox

- Carmen Christiansen
- Joanne Amberson
- Becky Packer
- Simon Robertson
- Carolyn Tallack
- Kathleen McFadden
- Jae Yon Jones





Rotary Manor

Clear Committee members, past and present:

- Julie Lee Residential
 Carolyn McCurdy Care Coordinator
- Maija Vesaniemi Charge Nurse (DC2)
- Barbara Tivadar Recreation Coordinator

- Clerk III
- Candace Yaciw, Charge Nurse





Eden Gardens

Clear Committee members, past and present:

Denise-DOC

Dr Dodo-MRP

- Diana-RN
- Kim-LPN
- Tara-LPN
- Dr Javaheri-MD
- Dr Kerridge-MRP
- Dr Fletcher-MRP






YOUR DATA ACCOMPLISHMENTS!






Teams Reporting over Time

Teams Completing Monthly Reports



Team Attendance at Events/Webinars









Antipsychotic Use: All Clear Teams

% of residents on any antipsychotics (total use)



% of residents on antipsychotics without a diagnosis of psychosis (potentially inappropriate)








Antipsychotic Use: All Clear Teams

% of residents on any antipsychotics (total use)








Antipsychotic Use: Teams reporting since August (n=14)

 % of residents on antipsychotics without a diagnosis of psychosis (potentially inappropriate)







Cumulative Progress

In a sample of ~1760 residents, there were:

- 97 residents with antipsychotics discontinued
- 58 residents had antipsychotics reduced


This translates to 1 out of 10 residents on antipsychotics impacted by improvement work






Team Self-Assessments

Number of Reporting Teams



Average Score







MEET YOUR HEALTH AUTHORITY LEADS





Region	Name	Email
Fraser Health	Anita Wahl	anita.wahl@fraserhealth.ca
Interior Health	Clarissa Frausel	Clarissa.Frausel@interiorhealth.ca
Island Health	Catrin Brodie	catrin.brodie@viha.ca
Northern Health	Marcia Bertschi	Marcia.Bertschi@northernhealth.ca
Vancouver Coastal Health	Jas Gill	jasjit.gill@vch.ca





Clear Website

Clear

Clear is supporting long-term care homes to carry out effective behavioural care planning and management that will lead to a reduction in the number of their residents who are prescribed antipsychotic medications. **Wave 3 of Clear launched in**December 2017 and is currently underway, with 41 participating care homes.

Interested in getting an idea of what has been happening in BC addressing antipsychotics in long-term care? Have a look at this BCCPA report: A Pathway to Ensuring the Appropriate Use of Antipsychotics in Continuing Care.

Read the latest Clear Newsletter!

Jump To:







Teams

Physicians

Families & Caregivers





Evaluation - Initial Data

- Coding of all data sources across the themes, strategies and barriers (to inform transition and sustainment planning)
 - Regional workshops
 - Mid initiative survey
 - Monthly reports
 - Storyboards
 - Our conversations with YOU!





Evaluation – Survey THANK YOU!

- 48 total responses
- 24 unique care homes
 - More than half of participating sites!
- Heard from all levels of leadership
 - Director of Care
 - LPN
 - Pharmacists
 - Recreation/ Occupation Therapists





Has participating in Clear helped you to improve teamwork and communication within your care team? If so, how?

- 93% of respondents said Yes
- "It has been a project that has involved the entire team resulting in a sense of community."
- "Staff are now aware that antipsychotics are not the first line of treatment and that there are benefits to taking people off of them."





Which specific change idea(s) have you found had the greatest impact in your care home?

- Behavior tracking tool
- Talking to families about why their loved one is on an antipsychotic
- A bedside "getting to know me" tool
- Training and huddles: getting every one on the same page





Evaluation Next Steps

- Interviews (May 2019)
- Final data updates (Summer 2019)
- Clear Wave 3 evaluation report (Fall 2019)
- Economic evaluation component (Fellowship)





Clear Evaluation

- Aiming to release by end of October 2019
- Look for the report in your email!






Cannabis in the Elderly

Dr. Nouha Ben Gaied





DR. NOUHA BEN GAIED





Sociétés Alzheimer

Why should we (or not) consider cannabis in LTC?


Nouha Ben Gaied, *PhD*Director R&D and QoS

BC Patient safety and quality council May 16th, 2019

- 1. Alzheimer's disease
- 3. Cannabis
- 4. State of the Art

ALZHEIMER'S DISEASE

THE BRAIN



AD IN NUMBERS



Over 70,000 pleople in BC are living with dementia 565,000 Canadians are affected

In 2025, more than 1.4 million in Canada)



65 % are women

70 % of caregivers are women



9 person receive a diagnostic every **hour**



Cost on our healthcare system: over 10.4 billion \$ per year



After 65, the risk **double** every 5 years

CHALLENGES IN AD

- Alzheimer's disease is a neurodegenerative disease;
- Alzheimer's disease is not part of the normal aging process.
- Alzheimer's disease is the most common form of dementia*

We do not have a cure


T

We don't know its causes



THE 10 WARNING SIGNS





DIFFICULTY PERFORMING FAMILIAR TASKS

Forgetting how to do something you've been doing your whole life, such as preparing a meal or getting dressed



PROBLEMS WITH LANGUAGE

Forgetting words or substituting words that don't fit the context.



DISORIENTATION IN TIME AND SPACE

Not knowing what day of the week it is or getting lost in a familiar place.



IMPAIRED JUDGMENT

Not recognizing a medical proble that needs attention or wearing light clothing on a cold day.




PROBLEMS WITH ABSTRACT THINKING

Having difficulty balancing a chequebook, for example, or not understanding what numbers are and how they are used.



MISPLACING THINGS

a dress in the refrigerator or a wristwatch in the sugar bowl.



CHANGES IN MOOD AND BEHAVIOUR

xhibiting severe mood swings from eing easy-going to quick-tempered



CHANGES IN PERSONALITY

Behaving out of character, such as becoming confused, suspicious, o



LOSS OF INITIATIVE

osing interest in friends, family nd favourite activities.

TREATMENT OPTION

There is currently no cure for Alzheimer's disease and other dementias, nor is there a treatment that will stop the progression. Several <u>drugs</u> on the market and <u>non-pharmacological treatments</u> may help with some symptoms like memory loss, language, cognitive function and mobility.









CANNABIS LEGALIZATION

THE CANNABIS ACT

- ✓ In 2001, Canada became the first country to allow the use of cannabis for therapeutic purposes
- ✓ In October 17, 2018, Canada became the 2nd country to legalise cannabis for recreation usage with law C-45

THE CANNABIS ACT

The Cannabis Act creates a strict legal framework for controlling the production, distribution, sale and possession of cannabis across Canada.

The Act aims to accomplish 3 goals:

- keep cannabis out of the hands of youth
- keep profits out of the pockets of criminals
- protect public health and safety by allowing adults access to legal cannabis

The Government of Canada has committed close to \$46 million over the next five years for cannabis public education and awareness activities.

THE CANNABIS ACT



Individual possession

150g/person

At home

Individual possession
30g/person
Public area

4 cannabis plants per residence allowed by the Cannabis act.

It is prohibited for any person to drive a road vehicle or to have care or control of a road vehicle if there is a detectable presence of cannabis or other drug in the person's saliva.'

Driving license withdrawal for a period of 90 days



CANNABIS, THE PLANT

Different names: Pot, marijuana, mari, weed, herb;

Can be presented under various forms: tablets, liquid or oil;

Can be consumed by: smoking, ingestion, inhalation, vaporazing, applied locally.

3 species: Indica, Sativa, Hybride



Indica

RELAXING

- Calming and relaxing effects
- Can induce drowsiness

STIMULATING

- More energy
- Increased concentration and creativity

COMPOSITION



<u>The flower</u>: Consumed for its high level of cannabinoids

The trichome: Contain THC and CBD Little crystal present all over the plant Bigger and high number on the flower

The Leaf: Symbol of cannabis.


Easily recognizable:

Pronounced venation and serrated leaflets

Plant very rich in <u>terpenes</u> that provide aromas and various intense flavor to the plant: lemon, fruity, sweet, woody, spicy, earthy...

Plant very rich in <u>cannabinoids</u>, more than 10 varieties, including dont THC CBD and Cannabinol (CBN).


COMPOSITION



Tetrahydrocannabinol **THC**

Psychotropic, euphoriants effects; "high" effect;

At a higher concentration can lead to: paranoia and anxiety.



Cannabidiol CBD

Lower concentration; Very little psychotropic properties; Known for its medicinal properties; Can reduce the effect of THC.

Standardized preparation: flower 0.27-22% THC, 0.5-13% CBD

Cannabis oil: 1-18.3% THC, 0.2-20% CBD

EFFECTS ON THE BRAIN

Synthocannabinoids

Phytocannabinoids



Anandamide Endocannabinoids



System participate into the regulation of our body:
Appetite, pain, pleasure, immune system,
mood, memory.

CB1 Receptor
Central nervous system:
Brain, nerves and ramifications

Psychoactive Effects

THC > CBD

CB2 Receptor
Immune system cells:
Macrophages

Regulation immune and inflammatory response

THC < CBD < CBN

THERAPEUTIC USE OF CANNABIS

In Canada, prescription of cannabis for medical reasons is allowed by a doctor under the *Controlled drugs and substances act*.

HOWEVER

Cannabis is not fully considered as a drug as it hasn't been approved for medical usage under the *food and drugs act*

A medical certificate can be provided to treat:

- Severe nausea et vomiting (chemotherapy)
 - Pain and spasm (Multiple sclerosis)
- Symptoms in palliative care and end of life

In 2017, 2475 medical certificate delivered

EFFECTS OF CANNABIS

Neurobiological activity

- Dopaminergic activation
- Decrease in the Acetylcholinergic activity (Hippocampus)

Symptoms

- Euphoria
- Anxiety
- Delirium
- Hallucinations
- Panic
- Aggressiveness
- Perception disorder
- Attention disorder
- Memory loss (short term memory)

WHAT ABOUT OUR ELRDERLY?

A special reality:

- Aging population, at home or in long term care
- Deterioration or disfunction in certain organs;
- Pharmacokinetic, pharmacodynamic changes;
- Polypharmacy.



Use of Cannabis:

Higher risk, more frequent side effects and drug interaction; Prescribing medicinal cannabis become more difficult.

RESPONSIVE BEHAVIOUR

- > 70-80% of LTC resident have dementia
- 90% of all residents in LTC have BPSD*
- Responsive bevahiour: agitation, aggression, paranoia, depressive behaviors, wandering, delirium, hallucinations, sleep disorders, sexual behaviours;
- Look for the reasons/causes.
- Physical, Intellectual,
- Emotional
- Capabilities
- Environment
- Social
- Actions of others



Treatment of BPSD: communication approach; nonpharmacological approaches; Medication when **needed**

THERAPEUTIC EFFECTS (1)

Fundamental research in vitro & in vivo showed an effect on:

Anxiety;

Insomnia;

Very little effects on elderly

Arthritis;

Anorexia;

Certain tumor and cancer.

A recent study showed a beneficial effect on:

- The quality of life in the elderly population;
 - Reduced risk of falls;
 - Decrease use of certain drugs (opioids).

THERAPEUTIC EFFECTS (3)



Marinol® (dronabinol, USA)

- Orale administration
- Synthetic THC
- Treatment of nausea, vomiting in chemotherapy and weight loss with HIV patient
- Pills of 2.5, 5 and/or 10mg



Cesamet® (nabilone, Canada)

- Orale administration
- Dronabinol analog
- Treatment of nausea and vomiting (chemotherapy)
- Pill of 1mg.

Sativex®: (Canada, EU, Latin America): Oral spray, THC+CBD 1/1, MS treatment

CANNABIS AS A CURE?

No studies or clinical trials have looked at the effects of cannabis, or any of its derivatives, to learn more about the causes of Alzheimer's disease or to improve cognitive functions.

EFFECT of NABILONE

- Study lead by Dr Krista Lanctôt;
- ➤ 14-week randomized, double-blinded trial;
- Administration of Nabilone (6 weeks), 1 week of rest, followed by placebo (6 weeks);
- 38 adults with moderate to severe Alzheimer's disease who live at home or in long-term care;
- > 77% of men, mean age 87 years;

RESULTS SO FAR

Evaluation:

- Behaviour symptoms;
- Memory;
- Physical changes.

Results: (compared to placebo)

- ✓ Significant improvement in agitation symptoms;
- ✓ Significant improvement in behaviour symptoms;
- ✓ A slight improvement in cognition and appetite.

BUT

A sedation effect is observed in 45% of participant (16% placebo)

A NEW TRIAL

- Lead by researcher at King's College London
- First major UK clinical trial to address behaviour symptoms using SATIVEX®
- 60 volunteer with symptoms of dementia and Alzheimer's disease
- Elderly in nursing or assisted living homes
- > Age 55-90 years old

WHAT YOU NEED TO REMIMBER

- ➤ Make the difference between THC and CBD;
- Promising results to treat behavioral symptoms;
- No studies have demonstrated the effect of cannabis or any of its derivatives on cognition or memory;
- Studies in people with Alzheimer's disease are still at an early stage.
- Larger cohorts should be enrolled to confirm the observed results;
- The legalization of cannabis will certainly support research in this area.

Sociétés Alzheimer

THANK YOU.

Q&A

SUMMARY AND CLOSE









